Fidia Spa (IT:FDA) has released an update.
Fidia S.p.A. has reported a challenging first half of 2024, with a slight increase in net revenues to €9.4 million but a significant worsening in net results to a negative €7.2 million, impacted by convertible bonds and issued warrants. Despite setbacks in order acquisition and a delayed industrial plan due to the machine tool sector crisis, the company anticipates a stronger performance from 2025 with new product developments in the CNC and HSM segments.
For further insights into IT:FDA stock, check out TipRanks’ Stock Analysis page.
